Navigation Links
Oracle Buys Relsys
Date:3/23/2009

Adds Advanced Drug Safety and Risk Management Applications to Extend Oracle's Leadership in Health Sciences

REDWOOD SHORES, Calif., March 23 /PRNewswire-FirstCall/ --

News Facts

  • Oracle today announced that it has agreed to acquire Relsys International, Inc. ("Relsys"), a leading provider of drug safety and risk management solutions with advanced analytics for the health sciences industry.
  • Relsys' best-in-class solutions support adverse event reporting, risk management, and data analysis for pharmaceutical, biotechnology, contract research organizations and medical device companies worldwide.
  • The combination of Oracle and Relsys is expected to deliver the only suite of software applications that supports end-to-end drug safety processes across clinical development, post-market surveillance and patient care, and is expected to extend Oracle's leadership in providing drug safety applications to the health sciences industry.
  • The addition of Relsys will bring significant domain knowledge and experience as part of Oracle's Health Sciences Global Business Unit, and is consistent with Oracle's strategy to provide mission-critical applications for key industries.
  • The transaction is subject to customary closing conditions and is expected to close in the first half of calendar year 2009.
  • Until the deal closes, each company will continue to operate independently.
  • Financial details of the transaction were not disclosed.

Supporting Quotes

  • "The health sciences industry is increasing investments in software that provide greater transparency into drug safety and help improve the overall safety of therapies," said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. "With the addition of Relsys, Oracle is uniquely positioned to help our customers improve drug safety by delivering a comprehensive software solution that enables our vision of integrated safety and risk management supported by advanced analytics."
  • "Identifying safety issues earlier in the development process can significantly reduce the costs and risks associated with bringing drugs and devices to market," said Dave Bajaj, President & CEO, Relsys. "Industry leaders trust Relsys' solutions to help them capture these benefits. We look forward to joining Oracle and helping provide the health sciences industry with the most complete, open and integrated suite of enterprise software."

Supporting Resources

About Oracle

Oracle (Nasdaq: ORCL) is the world's largest business software company. For more information about Oracle, please visit our Web site at http://www.oracle.com/.

Trademarks

Oracle is a registered trademark of Oracle Corporation and/or its affiliates. Other names may be trademarks of their respective owners.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020718/ORCLLOGO)


'/>"/>
SOURCE Oracle
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. TCS, Oracle and DrugLogic Prescribe Safety in a Capsule(TM)
2. Oracle Helps Mayo Clinic Improve Information Management
3. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
4. Oracle Introduces Remote Data Capture Onsite 4.5.3 With Extensive New Functionality for Investigative Site Personnel
5. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
6. Oracle Healthcare Acquisition Corp. Changes Record Date and Date of Special Meeting to Consider and Vote on Dissolution and Plan of Liquidation
7. Oracle Healthcare Acquisition Corp. Announces Stockholder Approval of Proposed Dissolution and Plan of Liquidation
8. MedTrust Online Collaborates With Oracle and Dell to Provide Oncologists With the Next Generation Tool for Personalized Care Delivery
9. Vgo Software First to Convert Oracle Forms to Oracle ADF v11
10. Sermes CRO Deploys Oracle(R) Clinical Applications to Support Growth
11. Bruce Palsulich Joins Relsys International as Chief Innovation & Strategy Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: